Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 8/20 | 0.37 |
| ▸ | MAOA | P21397 | 5/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 4/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4487957 | 0.91 | SLC2A1 (0.39) | SLC2A1PTPN1DAOPLAT | |
| SCHEMBL4468891 | 0.89 | SLC2A1 (0.51) | SLC2A1MAOBMAOAHCAR2PLAT | |
| SCHEMBL4469243 | 0.89 | MAOB (0.34) | MAOBMAOA | |
| SCHEMBL4476498 | 0.88 | RHEB (0.38) | MAOBDAOPPARD | |
| SCHEMBL4476162 | 0.88 | SLC2A1 (0.51) | SLC2A1MAOBMAOAHCAR2PTPN1 | |
| SCHEMBL4484456 | 0.83 | ACHE (0.32) | — | |
| SCHEMBL4480633 | 0.81 | DAO (0.49) | SLC2A1DAO | |
| SCHEMBL4565035 | 0.81 | TNKS (0.39) | SLC2A1MAOBMAOADAO | |
| SCHEMBL4493329 | 0.78 | SLC2A1 (0.52) | SLC2A1PTPN1DAOPLATPPARG | |
| SCHEMBL4481124 | 0.77 | SLC2A1 (0.65) | SLC2A1MAOBMAOAHCAR2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | claimed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | claimed |
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| EP-1858876-A2 | PYRIDINONE DERIVATIVES AGAINST MALARIA | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094799-A2 | PYRIDINONE DERIVATIVES AGAINST MALARIA | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | G6PD, PNPO, PLPBP | SLC2A1 2278/4885MAOB 351/4885MAOA 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.